Long-acting amylin analogue

Category

Amylin

ID

NNC0174-0839

Amount per vial

1000 nmol

Amylin is a 37-amino acid peptide that is stored in pancreatic beta cells and co-secreted with insulin. Amylin is an important regulator of energy metabolism and belongs to the calcitonin peptide family. Amylin acts via amylin receptors have mainly been identified in the hind brain. The amylin receptor consists of a calcitonin receptor (several splice variants) which heterodimerizes with one of three receptor activity-modifying protein (RAMP) splice variants thus generating many possible amylin receptor subtypes with different pharmacological properties.

NNC0174-0839 is a dual-acting amylin analogue with agonistic effects on the amylin receptor as well as the calcitonin receptor. NNC0174-0839 have been designed to be long-acting in vivo. The main mechanism for the extended half-life is albumin binding.

Category

Amylin

ID

NNC0174-0839

Amount per vial

1000 nmol

Download data sheet
Selected calculated properties for NNC0174-0839 and rat amylin (NNC0174-4010)
Property
NNC0174-0839
Rat amylin (NNC0174-4010)
MW [Da]4479.13920.4
pI7.013.3
Fatty acidC20 diacid-
LinkergGlu-
Extinction coefficient 280 nm16151615
Sum formulaC200 H310 N54 O59 S2C167 H272 N52 O53 S2

Figure 1

2D sketch of NNC0174-0839. NNC0174-0839 has a C20 fatty diacid side chain which is attached via a glutamic acid linker to the N-terminal. The fatty acid side chain enables reversible binding to serum albumin in the blood stream, which increases the half-life of the molecule.

In vitro potency data of NNC0174-0833(cagrilintide), NNC0174-0839, salmon calcitonin and pramlintide (derived from Gabery S et al., Life Sci. 2025 Jul 6;378:123845 (Reference 1 below))

The in vitro data for NNC0174-0839 and the other compounds in the table are based on cellular assays using cloned receptors in Baby Hamster Kidney (BHK) cells. The BHK cell line was stably transfected with calcitonin receptor subtype a (CTR(a)) and/or receptor modifying protein 3 (AMY3(a)R) of mouse, rat or human species. Cell models with rat and human receptors were also stably transfected with a cAMP responsive element (CRE) luciferase reporter gene. The in vitro potency assays with mouse receptor cell models (FRET based) were performed in the absence of human serum albumin (HSA) in buffer containing 1% ovalbumin, while those with rat or human receptor cell models (luminescence based) were performed in the absence or presence of 1% (w/v) HSA in buffer containing 1% ovalbumin. Since albumin binding is a key mechanism for the design of NNC0174-0839, be aware that the apparent affinity and potency will be very dependent on whether the in vitro assay contains albumin or not.

Compound

Mean EC50, (95% CI), [M]

No HSA

1% HSA

No HSA

1% HSA

Mouse AMY3(a)R

Mouse CTR(a)

0833 (Cagrilintide)

1.49E-11 
 (9.08E-12 to 2.45E-11)

NA

7.96E-12 
(4.54E-12 to 1.40E-11)

NA

0839

1.70E-11 
 (1.10E-11 to 2.61E-11)

NA

1.99E-11 
 (6.39E-12 to 6.22E-11)

NA

sCT

4.88E-13 
 (3.05E-13 to 7.81E-13)

NA

2.83E-13 
(1.61E-13 to 4.99E-13)

NA

Pramlintide

3.61E-12 
 (1.38E-12 to 9.47E-12)

NA

3.87E-11
 (4.43E-12 to 3.38E-10)

NA

 

Rat  AMY3(a)R

Rat CTR(a)

0833 (Cagrilintide)

1.86E-12 
(1.09E-12 to 3.16E-12)

2.32E-11 
 (1.62E-11 to 3.34E-11)

5.89E-12 
(4.47E-12 to 7.77E-12)

1.67E-10 
 (9.88E-11 to 2.82E-10)

0839

2.28E-12 
 (1.52E-12 to 3.42E-12)

2.43E-11 
 (1.52E-11 to 3.88E-11)

5.63E-12 
(3.62E-12 to 8.76E-12)

1.54E-10 
(8.01E-11 to 2.98E-10)

sCT

2.59E-12 
(1.63E-12 to 4.11E-12)

1.56E-12 
(1.19E-12 to 1.51E-12)

3.40E-12 
 (2.48E-12 to 4.65E-12)

1.92E-12 
 (7.53E-13 to 4.91E-12)

Pramlintide

2.82E-12 
(1.11E-12 to 7.16E-12)

1.72E-12
 (1.21E-12 to 2.43E-12)

1.75E-10 
(1.14E-10 to 2.68E-10)

1.06E-10 
 (6.99E-11 to 1.61E-10)

 

Human AMY3(a)R

Human CTR(a)

0833 (Cagrilintide)

1.85E-12
 (1.53E-12 to 2.23E-12)

5.85E-11 
 (3.99E-11 to 8.57E-11)

2.62E-12 
 (1.98E-12 to 3.46E-12)

5.45E-11 
 (3.40E-11 to 8.73E-11)

0839

3.18E-12 
(2.62E.12 to 3.87E-12)

1.31E-10 
 (9.72E-11 to 1.77E-10)

3.56E-12 
 (2.40E-12 to 5.28E-12)

1.03E-10 
(6.47E-11 to 1.63E-10)

sCT

2.52E-12 
(1.74E-12 to 3.65E-12)

1.59E-12 
 (1.19E-12 to 2.13E-12)

4.07E-12 
 (2.82E-12 to 5.87E-12)

2.96E-12 
 (1.21E-12 to 7.25E-12)

Pramlintide

3.41E-12 
 (2.13E-12 to 5.46E-12)

2.31E-12 
(2.17E-12 to 2.47E-12)

2.46E-11 
 (2.13E-11 to 2.84E-11)

2.34E-11 
 (1.30E.11 to 4.23E-11)


AMY3(a)R: amylin receptor with RAMP3; CTR(a): calcitonin receptor subtype a; HSA: human serum albumin

The pharmacokinetic (PK) and pharmacodynamic (PD) properties of amylin can be assessed in various animal models; however, pigs are not a suitable model for PD studies.

Unlike other known amylin receptor agonists such as salmon calcitonin and pramlintide, NNC0174-0839 can bind to serum albumin and therefore displays a significantly longer half-life. In mini-pigs, NNC0174-0839 displays a terminal half-life (T1/2) of 110 h following a s.c. administration of a single dose of 10 nmol/kg.

The pharmacodynamic properties of amylin such as appetite reduction and reduction of body weight can be studied in rats. The effect on food intake (FI) in lean Sprague Dawley rats after s.c. administration of a single dose of NNC0174-0839 given prior to onset of the dark phase is shown in the table below. The reduction in accumulated food intake is reported relative to vehicle-treated rats within the same study.

DoseFI reduction 0-24 h
(%)		FI reduction 24-48 h
(%)		FI reduction 0-48 h
(%)
3 nmol/kg492537


A more comprehensive characterisation of  the pharmacodynamic properties of NNC0174-0839 in lean and diet induced obesity (DIO) rodent models is available in the study by Gabery S et al., Life Sci. 2025 Jul 6;378:123845 (Reference 1 below).

Adverse effects

Amylin analogues can cause gastro-intestinal side effects such as nausea and feeling of malaise. Therefore, dose escalation should be introduced if doses higher than 10 nmol/kg is being investigated in rats. Doses can be escalated every third day.

NNC0174-0839 also induce acute hypocalcaemia in young rodents, especially in rats. This can potentially lead to serious side effects and even death, so stress should be avoided prior to dosing and Sprague Dawley rats from Janvier Labs should not be used for in vivo experiments since these are very sensitive to the hypocalcaemia-inducing properties of NNC0174-0839.

Rat amylin (NNC0174-4010) is available as a reference compound to NNC0174-0839. Please indicate (with a check mark at ‘Please add the reference compound if available) during your compound request if you would like to have NNC0174-4010 included in your shipment.
Peptides and proteins tend to adhere to glass and plastic surfaces. This may at low concentration impact the actual amount in solution. To minimize this unspecific adherence, adding detergents or inert proteins like e.g., ovalbumin or other serum albumins to the solution can minimize this phenomenon. In case albumins are added to peptide/protein solutions, ensure that the albumins are free of any proteases, but be aware that it will affect the apparent potency and affinity in in vitro assays in case a fatty acid is attached to the compound. For in vitro studies, NNC0174-0839 and NNC174-4010 (rat amylin) can be dissolved in 80/20% DMSO/MilliQ water (e.g. at a concentration of 300 uM). NNC0174-0839 can be dosed in vivo in a formulation vehicle containing 5mM sodium acetate, 240mM propylene glycol, (0.007% polysorbate 20 if concentrations are so low that adsorption to vials may affect the concentration), pH 4.0. It is always recommended to evaluate compound stability over the entire length of the experiment. Formulations can be used fresh for up to one week if stored refrigerated. Formulations can also be aliquoted and frozen for up to three months.

Gabery S et al.

Characterization of 0839 – A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide

Life Sci. 2025 Jul 6;378:123845

DOI PubMed
DOI
PubMed

Zakariassen HL et al.

Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases

Basic Clin Pharmacol Toxicol. 2020;00:1–15.

DOI PubMed
DOI
PubMed

Hay DB et al.

Amylin: Pharmacology, Physiology, and Clinical Potential

Pharmacol Rev, 2015 Jul;67(3):564-600

DOI PubMed
DOI
PubMed

Andrew Young

Amylin, Physiology and Pharmacology, Volume 52, 1st Edition

Hardcover ISBN: 9780120329540; eBook ISBN: 9780080916064; Imprint: Academic Press; Published Date: 12th December 2005

DOI PubMed
DOI
PubMed